Analysis updated on Nov. 6, 2026 (UTC) · Total · absolute moveSwitch to Alpha · Nasdaq
Our AI scores Livanova Plc every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Livanova Plc is a mid-cap company with a market capitalization of $5.02B. It ranks number 2 by market capitalization among the 28 Electromedical & Electrotherapeutic Apparatus issuers in our coverage with a current forecast.
For LIVN, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 50.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 30.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +6.2%, buy ≥ +4.2%, sell < +2.2%, strong sell < +0.5% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-11-06 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, LIVN included.
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Electromedical & Electrotherapeutic Apparatus peers listed below that report each metric.
| Metric | LIVN | Rank |
|---|---|---|
| Market Cap | $5.02B | 2/28 |
| P/E Ratio | 34.92x | 2/9 |
| P/B Ratio | 3.66x | 11/22 |
| EPS | $2.61 | – |
| Book Value/Share | $24.90 | – |
| Revenue/Share | $27.35 | – |
| FCF/Share | $2.34 | – |
| Metric | LIVN | Rank |
|---|---|---|
| ROE | 14.3% | 4/15 |
| ROA | 7.2% | 4/18 |
| ROIC | 8.2% | 6/20 |
| Gross Margin | 67.5% | 10/25 |
| Operating Margin | 10.8% | 5/25 |
| Net Margin | 13.0% | 5/17 |
| EBT Margin | 7.9% | 6/25 |
| Tax Rate | -64.3% | – |
The effective tax rate is outside the normal band, which points to a large non-recurring tax item in the trailing twelve months; headline net income, net margin and P/E are affected by it.
| Metric | LIVN | Rank |
|---|---|---|
| Current Ratio | 1.46x | 20/27 |
| Quick Ratio | 1.22x | 17/26 |
| D/E Ratio | 0.98x | 9/23 |
| Financial Leverage | 1.98x | 9/23 |
| Interest Coverage | 1.4x | 10/27 |
| Working Capital | $343M | 6/26 |
| Metric | LIVN | Rank |
|---|---|---|
| Operating Cash Flow | $238M | 2/27 |
| Free Cash Flow | $129M | 2/14 |
| Capital Spending | -$109M | 13/14 |
| OCF Growth YoY | -5.1% | 4/7 |
| FCF Growth YoY | -32.6% | 5/6 |
| FCF/Sales | 8.6% | 3/14 |
| CapEx/Sales | 7.2% | 2/14 |
| Metric | LIVN | Rank |
|---|---|---|
| Asset Turnover | 0.56x | 8/17 |
| Receivables Turnover | 6.4x | 7/19 |
| Inventory Turnover | 2.8x | 9/25 |
| Fixed Assets Turnover | 5.1x | 14/19 |
| Days Sales Outstanding | 57 days | 13/19 |
| Days Inventory | 133 days | 17/25 |
| Payables Period | 80 days | 11/23 |
| Cash Conversion Cycle | 110 days | 12/18 |
| Metric | LIVN | Rank |
|---|---|---|
| Total Revenue | $1.51B | 3/18 |
| Operating Income | $162M | 2/27 |
| Net Income | $196M | 2/19 |
| R&D Expense | $212M | 2/26 |
| SG&A Expense | $595M | 3/24 |
| Cost of Goods Sold | $489M | 4/25 |
| Metric | LIVN | Rank |
|---|---|---|
| Shares Outstanding | 55M | – |
| Total Current Assets | $1.08B | 39.9% of assets |
| Cash & Short-term Investments | $563M | 20.8% of assets |
| Accounts Receivable | $236M | 8.7% of assets |
| Inventory | $178M | 6.6% of assets |
| Total Liabilities | $1.34B | 49.4% of assets |
| Short-term Debt | $633M | 23.3% of assets |
Companies classified under the same SEC industry code as Livanova Plc (Electromedical & Electrotherapeutic Apparatus): 29 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| LIVN Livanova Plc | $5.02B | |
| MDT Medtronic Plc | $134.10B | |
| ITGR Integer Holdings Corp | $4.31B | |
| AXGN Axogen, Inc. | $2.91B | |
| TMDX Transmedics Group, Inc. | $2.39B | |
| CNMD Conmed Corp | $1.57B | |
| CBLL Ceribell, Inc. | $998M | |
| INMD Inmode Ltd. | $770M | |
| CV Capsovision, Inc | $310M | |
| ELMD Electromed, Inc. | $224M | |
| FOCL Edap Tms Sa | $159M | |
| STXS Stereotaxis, Inc. | $105M | |
| VANI Vivani Medical, Inc. | $95M | |
| ECOR Electrocore, Inc. | $79M | |
| OM Outset Medical, Inc. | $77M | |
| NRXS Neuraxis, Inc | $77M | |
| HYPR Hyperfine, Inc. | $73M | |
| POCI Precision Optics Corporation, Inc. | $54M | |
| POSC Positron Corp | $54M | |
| QTI Qt Imaging Holdings, Inc. | $30M | |
| ITOC Itonic Holdings Ltd | $12M | |
| IRIX Iridex Corp | $12M | |
| GTHP Guided Therapeutics Inc | $10M | |
| NDRA Endra Life Sciences Inc. | $8M | |
| ADMT Adm Tronics Unlimited, Inc. | $6M | |
| NUWE Nuwellis, Inc. | $2M | |
| ESMC Escalon Medical Corp | $1M | |
| NXL Nexalin Technology, Inc. | $1M | |
| YBGJ Yubo International Biotech Ltd | N/A |
LivaNova PLC reported earnings results for the third quarter and nine months ended September 30, 2026. For the third quarter, the company reported sales was USD 393.1 million compared to USD 357.8 million a year ago.
LivaNova Q3 2026 earnings: revenue rose 10%, guidance increased, and OSA reimbursement progress improved outlook.
Detailed price information for Livanova Plc OR Sh (LIVN-Q) from The Globe and Mail including charting and trades.
Our AI scores Livanova Plc every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
For LIVN, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 50.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 30.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Livanova Plc forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 6, 2026.
29 issuers in our coverage, LIVN included, share the SEC industry code Electromedical & Electrotherapeutic Apparatus. The largest are: Medtronic Plc (MDT), Integer Holdings Corp (ITGR), Axogen, Inc. (AXGN), Transmedics Group, Inc. (TMDX), Conmed Corp (CNMD), Ceribell, Inc. (CBLL).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.
Signals, companies, plans: answered from live data.
I read Intratio's daily model signals, company data and your account to answer in seconds, in your language.
